BioMarin Pharmaceutical Inc. has entered into a definitive agreement to acquire Amicus Therapeutics, a global patient-dedicated biotechnology company focused on developing novel medicines for rare diseases. The all-cash transaction is valued at approximately $4.8 billion and will be completed in the second quarter of 2026, subject to regulatory clearances and other customary closing conditions.
The acquisition adds two high-growth products, Galafold (migalastat) for Fabry disease and Pombiliti + Opfolda (cipaglucosidase alfa-atga + miglustat) for Pompe disease, to BioMarin’s existing portfolio of medicines. Both products have shown strong revenue growth, with combined net product revenues over the past four quarters totaling $599 million.
The transaction is expected to accelerate BioMarin’s revenue growth and strengthen its financial outlook immediately after close. The acquisition is also expected to be accretive to non-GAAP diluted earnings per share (EPS) in the first 12 months post-close and substantially accretive beginning in 2027.
BioMarin’s President and CEO, Alexander Hardy, stated that “Amicus, like BioMarin, is a company that has been profoundly dedicated to transforming care for patients with rare diseases since its founding. We believe this acquisition will accelerate our revenue growth and strengthen our financial outlook.”
The acquisition is the latest move by BioMarin to expand its position as a leader in rare disease treatments. The company has already established itself as a major player in the field, with eight commercial therapies and a strong clinical pipeline.
BioMarin will host a conference call today at 8:15 a.m. ET to discuss the acquisition and provide further information on the transaction.
Key Highlights:
* Definitive agreement to acquire Amicus Therapeutics for $4.8 billion
* Addition of high-growth products Galafold (migalastat) and Pombiliti + Opfolda (cipaglucosidase alfa-atga + miglustat)
* Expected to accelerate revenue growth and strengthen financial outlook
* Anticipated to be accretive to non-GAAP diluted EPS in the first 12 months post-close and substantially accretive beginning in 2027.
Source: https://investors.biomarin.com/news/news-details/2025/BioMarin-to-Acquire-Amicus-Therapeutics-for-4-8-Billion-Expanding-Position-as-a-Leader-in-Rare-Diseases-Accelerating-Revenue-Growth-and-Strengthening-Financial-Outlook/default.aspx